In animals, treatment with SFZYD for 4 weeks after the onset of obesity had no significant effects on fasting blood glucose levels, insulin levels, or homeostatic model assessment-insulin resistance (HOMA-IR) in obese mice (Figure A-C in S2 Fig). The gene discussed is INS; the disease is Obesity.